Drug Detail

Information about Bezuclastinib plus Sunitinib

Generic Name
Bezuclastinib plus Sunitinib
IND
CGT9486
Brand Name (US)
Manufacturer
Cogent Biosciences
Drug Type
Delivery
Oral
Approval Status
Indications
Overall Strategy
Inhibit KIT/PDGFRa
Strategy
Inhibit all resistant KIT/PDGFRa mutations
Drug Category
KIT inhibitor

Bezuclastinib
• Specifically targets KIT mutations
including exon 17 D816V
• Selective versus other targets including
wild-type KIT, PDGFRα, VEGFR2, FLT3 and
CSF1R